STRATEC SE (Frankfurt: SBS; Prime Standard) announced that shareholders at its Annual General Meeting held on June 23, 2026, approved all agenda items with clear majorities. The company will distribute a dividend of EUR 0.60 per share for the 2024 financial year, matching the previous year's dividend. The total distribution amounts to EUR 7.3 million and will be paid to shareholders via their depositing banks on June 26, 2026.
The approval of the dividend underscores STRATEC's commitment to sharing its financial success with shareholders. Despite a challenging economic environment, the company maintained its dividend payout, signaling stability and confidence in its business model. This decision is particularly significant for income-focused investors who rely on consistent returns.
In addition to the dividend, shareholders ratified the actions of the Board of Management and the Supervisory Board. They also elected PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft (PwC), Frankfurt am Main, as auditor for the 2026 financial year. The remuneration report was approved as well.
The meeting saw strong shareholder engagement, with 70.1 percent of the company's registered share capital represented. This high turnout indicates active interest in the company's governance and strategic direction.
STRATEC SE designs and manufactures fully automated analyzer systems for partners in clinical diagnostics and life sciences. The company also produces complex consumables for diagnostic and medical applications. Covering the entire value chain from development to production and quality assurance, STRATEC's partners market the systems, software, and consumables as integrated solutions to laboratories, blood banks, and research institutes worldwide.
The approval of all resolutions at the Annual General Meeting provides clarity for the company's future operations. The stable dividend may attract long-term investors, while the reappointment of PwC as auditor ensures continued financial oversight. For the broader industry, STRATEC's consistent performance reinforces its position as a reliable partner in the diagnostics and life sciences sectors.
Further details about the Annual General Meeting, including voting results, are available at www.stratec.com/agm.
